Osteosarcoma

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This study tests a drug called DS-8201a (trastuzumab deruxtecan) in children, teens, and young adults whose osteosarcoma, Wilms tumor, or desmoplastic small round cell tumor has come back or not responded to treatment. The drug works like a smart bomb, attaching to cancer cells a…

This early-phase trial tests the safety and best dose of cabozantinib combined with high-dose ifosfamide in 30 children and adults with sarcomas (like Ewing sarcoma or osteosarcoma) that have returned or not responded to standard chemotherapy. The goal is to find a dose that cont…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma, Ewing sarcoma, or osteosarcoma) have come back or not responded to treatment. The goal is to find a safe …

This study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…

This trial tests whether combining domatinostat with sirolimus can safely shrink or slow the growth of relapsed or refractory sarcoma and osteosarcoma in adolescents and adults aged 12 to 40. Participants must have already tried at least one standard therapy without success. The …

This phase II trial tests whether a single infusion of B7-H3 CAR T cells, given after standard chemotherapy, can prevent the return of high-risk osteosarcoma in children. The study will enroll 41 participants who have completed upfront chemotherapy. Researchers will monitor how l…

This early-stage trial is testing a new type of immune cell therapy called FH-FOLR1 ST CAR T-cells for people with advanced osteosarcoma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in a lab to recogniz…

This early-phase study tests a combination of two drugs—losartan (a blood pressure medicine) and sunitinib (a cancer drug)—in people aged 10 and older with osteosarcoma (a type of bone cancer) that has returned or not responded to treatment. The main goal is to find the safest do…

This trial is testing whether mifamurtide, a drug that stimulates the immune system to attack cancer cells, can improve outcomes for people with high-risk osteosarcoma, a type of bone cancer. Participants will be randomly assigned to receive either mifamurtide or the standard tre…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This study compares two types of surgery to remove lung tumors that have spread from osteosarcoma (a bone cancer). One method uses a single large cut (open surgery), while the other uses several small cuts and a camera (keyhole surgery). The goal is to see which approach helps pa…

This early-phase trial tests a combination of three drugs—selumetinib, ZEN-3694, and durvalumab—in people with advanced sarcomas, including malignant peripheral nerve sheath tumors (MPNST) linked to NF1. The study first checks safety and dosing, then looks at whether the treatmen…

This study tests a new treatment called afamitresgene autoleucel in children and young adults aged 2 to 21 with advanced cancers that have a specific marker (MAGE-A4). The treatment uses the patient's own immune cells, modified to attack the cancer. The main goals are to check sa…

This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…

This early-stage trial is testing whether adding disulfiram (a drug used for alcohol dependence) and copper gluconate to a standard chemotherapy (Doxil) is safe for people with sarcomas that have returned or not responded to prior treatments. About 24 participants will take these…

This early-stage study tests whether giving children with high-risk solid tumors a special type of immune cell (called TAA-T) is safe. The cells are designed to recognize and attack proteins found on tumor cells. Up to 36 children whose cancer has not responded to standard treatm…

This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…

This phase II trial is testing whether abemaciclib, a targeted cancer drug, can slow the growth of advanced bone and soft tissue sarcomas that have a specific alteration in the CDK pathway. Participants take the pill twice daily until their disease worsens or side effects become …

This early-stage trial is testing a new drug called AOH1996 in 92 adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The drug works by blocking a protein that cancer cells need to grow. The main goals are to fi…

This early-phase study tests a new combination of two different immune cells—NK cells and CAR-T cells—for children and young adults with neuroblastoma or osteosarcoma that has returned or not responded to standard treatments. The NK cells are designed to help the CAR-T cells work…

This study tests a new medicine called Risvutatug Rezetecan (Ris-Rez) in adolescents and adults with advanced bone or soft tissue sarcomas that have come back or spread and can't be removed by surgery. The goal is to see if the drug can slow cancer growth and how safe it is. Abou…

This early-phase study tests a chemotherapy drug (gemcitabine) given as a mist to breathe in. It is for people whose solid tumors have spread to the lungs and who have no standard treatment options. The main goal is to find the safest dose and watch for side effects. Up to 44 par…

This study tests whether adding eflornithine (DFMO) to standard chemotherapy can help teens and young adults with Ewing sarcoma or osteosarcoma live longer without their cancer coming back. About 406 participants will join one of five groups based on their cancer type and stage. …

This study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…

This phase 2 trial tests a daily oral drug called zanzalintinib in 70 adults with advanced or metastatic bone sarcomas that cannot be removed by surgery. The study includes four groups based on sarcoma type. Researchers will check if the drug is safe and helps control the cancer.

This study tests a drug called zanzalintinib (XL092) in 29 people with advanced leiomyosarcoma that has spread or cannot be removed by surgery. The drug works by blocking signals that help cancer cells grow. The goal is to see if it can slow the cancer's progression longer than c…

This early-phase trial tests a personalized cancer vaccine (SarcVac) combined with immune-boosting drugs and, in some patients, specially grown immune cells. The goal is to see if this approach is safe and can shrink tumors in 16 adults with advanced bone or soft tissue sarcoma w…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…

This early-phase trial is testing whether combining an immunotherapy drug (atezolizumab) with targeted radiation and surgery is safe for people whose osteosarcoma has come back in the lungs. About 12 participants will receive the drug, radiation to one lung nodule, and then surge…

This early-stage trial tests a new drug called tegavivint combined with the chemotherapy gemcitabine in 24 people whose osteosarcoma (a type of bone cancer) has returned or not responded to prior treatment. The main goal is to find the safest dose of tegavivint when given with ge…

This study tests a mistletoe extract (Iscador P) in 32 patients whose osteosarcoma has returned in the lungs and has been surgically removed. The goal is to see if the treatment can delay or prevent the cancer from coming back. Participants receive injections of the extract and a…

This study tests whether freezing tumors (cryoablation) combined with an immunotherapy drug (camrelizumab) can shrink advanced soft tissue sarcomas that have stopped responding to standard treatments. About 57 participants aged 14 to 70 will receive this combination. The main goa…

This study is for children and young adults (ages 1 to 30) whose solid tumors have come back or not gone away with standard treatment. It tests two different drug pairs: one combines Onivyde with talazoparib, the other Onivyde with temozolomide. Both work by damaging cancer cell …

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This study looks at whether a drug called dexrazoxane can help prevent heart damage in children and teens who have been treated for certain cancers like leukemia, lymphoma, and osteosarcoma. Researchers will measure heart function and blood markers in 420 survivors to see if dexr…

This study tests whether DFMO, a drug taken by mouth, can help prevent cancer from coming back in people with relapsed Ewing sarcoma or osteosarcoma who have finished all planned treatment and show no signs of disease. The trial will enroll 15 participants under age 40. The main …

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …

This expanded access program offers L-MTP-PE, an investigational drug that activates white blood cells to fight cancer, to people with osteosarcoma. Eligible patients include those with newly diagnosed or relapsed osteosarcoma who have had surgery to remove all detectable cancer.…

This early-phase trial is testing a new type of immunotherapy called B7-H3 CAR T cells in children and young adults whose solid tumors (such as neuroblastoma, sarcoma, or osteosarcoma) have come back or not responded to standard treatments. The therapy involves taking a patient's…

This early-stage trial is testing a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcomas that have stopped responding to standard treatments. The therapy uses the patient's own immune cells, modified to better recognize and attack cancer cells. The…

This study tests a new drug called LNTH-2403, which delivers radiation directly to cancer cells in people with osteosarcoma (a type of bone cancer) that has returned or not responded to standard treatments. The drug is given as an injection and aims to shrink tumors or slow their…

This study tests two drugs, atezolizumab and cabozantinib, in 40 adolescents and young adults (ages 12 and up) with osteosarcoma that has come back or spread. Atezolizumab helps the immune system attack cancer cells, while cabozantinib blocks enzymes that help tumors grow. The go…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has come back or not responded to standard therapy. The treatment uses the patient's own T-cells, which are modified in a lab to better recognize and attack cancer cells. The main goals …

This study tests a combination of two drugs, apatinib and liposomal irinotecan, in people with advanced osteosarcoma (bone cancer) that has spread or come back after standard treatments. The goal is to find the safest and most effective dose and see if the combo can shrink tumors…

This study tests whether adding four drugs (gefitinib, trametinib, disulfiram, and sunitinib) to standard chemotherapy helps people with osteosarcoma that has spread. About 45 participants with newly diagnosed or advanced disease will be enrolled. Researchers will check if the co…

This study is testing a bone marrow transplant from a half-matched family donor for people with high-risk solid tumors that have come back or not responded to treatment. Participants receive mild chemotherapy and radiation before the transplant, along with drugs to prevent reject…

This expanded access program provides DNG64-CAR-V, a gene therapy, to patients with advanced pancreatic cancer, sarcoma, or breast cancer who have exhausted standard treatments. The therapy is given intravenously or directly into tumors, alone or with other cancer drugs. Early st…

This phase 2 trial tests whether a year-long maintenance regimen of sirolimus (rapamycin) plus low-dose oral chemotherapy and celecoxib can improve 2-year survival without cancer progression in children with high-risk solid tumors. About 55 children and young adults (ages 1–30) w…

This study tests whether the drug regorafenib can help prevent bone sarcomas from coming back after initial treatment. About 168 people aged 12 and older with various bone sarcomas will be randomly assigned to take regorafenib for up to 12 months or to receive standard monitoring…

This phase 2 trial tests whether the drug regorafenib can help keep high-grade bone sarcomas from growing in patients who still have some disease after standard treatment. About 36 people aged 12 and older will take regorafenib daily for up to 12 months. The main goal is to see h…

This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have returned or not responded to treatment. The trial has two phases: first, finding the safest dose, then chec…

This early-stage study tests a new treatment for children and young adults up to age 21 with sarcomas that have come back or not responded to standard therapy. The treatment combines a special type of immune cell (B7-H3-CAR T cells) with targeted radiation and chemotherapy to see…

This study tests whether adding specially trained donor immune cells (NK cells) to standard chemotherapy can help children and young adults with sarcomas that have returned or not responded to treatment. About 50 participants aged 2 to 40 will receive up to 8 cycles of chemo plus…

This study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help t…

This early-phase trial is testing whether giving children with advanced neuroblastoma or osteosarcoma a special type of immune cell (gamma delta T cells) from a healthy donor, along with several standard cancer drugs, is safe and tolerable. The study will enroll 24 children aged …

This early-phase study tests a technique called in vivo lung perfusion (IVLP) that delivers chemotherapy directly into the lung during surgery to remove sarcoma tumors that have spread to the lungs. The goal is to kill any tiny cancer cells left behind that could cause the cancer…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This study tests two drugs, pembrolizumab and cabozantinib, together in people with advanced sarcomas (cancers of the soft tissue or bone) that have not responded to standard treatments. The goal is to see if the combination can stop or shrink tumors for at least 6 months. About …

This trial tests whether a new radioactive tracer, called 68Ga-B7-H3 nanobody, can safely and effectively highlight osteosarcoma tumors on PET/CT scans. Participants with relapsed or refractory osteosarcoma will receive a single injection of the tracer, followed by imaging to see…

This study tests a special dye called Cytalux that makes cancer cells glow under near-infrared light. Surgeons use it during lung surgery to find and remove hard-to-see tumors in teens (ages 6-17) with bone cancer that has spread to the lungs. The goal is to see if the dye helps …

This study compares whole-body MRI, PET/MR, and PET/CT scans to see which is best at finding tumors in children and young adults with solid tumors, lymphoma, or osteosarcoma. Researchers will check how many tumors each scan detects and measure their metabolic activity. The goal i…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This study collects and stores medical information from people treated for orthopaedic conditions like osteoarthritis, scoliosis, and cerebral palsy. Researchers at the University of Florida will gather data during routine clinical care to create a resource for future research. T…

This study follows 120 patients with localized osteosarcoma (a bone cancer) to collect information on their treatments and outcomes. It does not test a new drug but observes standard care to learn which approaches lead to better survival and fewer side effects. The goal is to imp…

This study will enroll 100 children with solid tumors or Hodgkin lymphoma who are receiving proton therapy. Researchers will take weekly or bi-weekly CT or MRI scans during treatment to check if the original radiation plan is still accurate. If tumor coverage drops by 5% or radia…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study is testing whether a smartwatch can track changes in walking and daily activities in people with bone cancer (osteosarcoma or metastatic bone disease). The goal is to see if the watch can help doctors spot problems early and personalize care. About 60 participants will…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study looks at how well children walk after having surgery for bone or soft tissue cancer in their legs. Researchers will use 3D cameras, muscle sensors, and wearable devices to measure movement in 300 children, comparing them to healthy kids of the same age. The goal is to …

This study is testing whether growing a patient's osteosarcoma cells in the lab (as organoids) can predict which chemotherapy drugs will work best. Researchers will take tissue from routine biopsies or surgeries of 40 people with suspected or confirmed osteosarcoma. The goal is t…

This study follows 300 people who had surgery to remove bone tumors (like osteosarcoma or chondrosarcoma). Researchers want to see how well the bone heals and how much function returns over 3 years. Participants fill out questionnaires about their daily activities. No new drug or…

This pilot study looks at 10 people with a new, high-grade bone cancer (osteosarcoma) in an arm or leg. The goal is to see if removing the tumor with surgery before starting chemotherapy leads to better arm or leg function and quality of life. Participants and their surgeons will…

This registry is collecting information from up to 9,000 people in Germany with sarcoma or carcinosarcoma. Researchers will track how often different subtypes occur, how they progress, and what treatments patients receive. The goal is to better understand these rare cancers and i…

This study looks at whether using 3D printed models of a patient's bones helps surgeons plan and perform tumor removal more effectively. About 150 people with bone tumors will take part, and half will have their surgery planned with both 3D models and regular scans, while the oth…

This study looks at how well bone cancer patients follow a personalized home exercise program in the first six months after lower leg surgery. Researchers will track daily exercise logs from 50 patients and explore what factors help or hinder adherence. The goal is to learn how t…

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the …

This study collects tumor and blood samples from 1,000 children with solid cancers like neuroblastoma and sarcoma. Researchers will analyze the genetic makeup and immune response of these tumors to better understand how they grow and resist treatment. The goal is to gather knowle…

This observational study is tracking 150 people whose high-grade osteosarcoma has come back near where it started. Researchers want to find out what factors affect how long people live after this type of relapse. The study will look at past and future cases to gather information …

This study is developing a new way to deliver chemotherapy directly to sarcoma tumors using tiny particles activated by light through an optic fiber. Researchers will test these nanoparticles on cells and tissue samples from 30 patients with bone or soft tissue sarcomas. The goal…

This study is a registry that will follow at least 300 people who need jaw reconstruction after having part of their jaw removed due to cancer or medication-related bone damage. Researchers will collect information on surgical methods, recovery times, and quality of life to learn…